AACC uses Cookies to ensure the best website experience. Continuing without changing Cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy

Wendy Alderton

Dr. Wendy Alderton, MA, PhD
Chief Scientific Officer, Abcodia Ltd, UK


Wendy Alderton  is currently Chief Scientific Officer at Abcodia Ltd and has been in her current role for the last 2 years. Wendy has over 15 years' experience in leading research groups in the biotech and pharmaceutical industries in areas that include oncology, small molecule drug discovery (at Millennium Pharmaceuticals in the UK), and at the PI3kinase pathway pioneers PIramed Ltd. She also has expertise in inflammation and neuroscience drug discovery from her 9 years at GlaxoSmithKline.

This included leading a team which delivered a compound into development that reached Phase II clinical trials. Wendy was also Managing Director of the Zebrafish Business Unit at Summit plc, which aimed to establish larval zebrafish as a model organism for efficacy and safety in drug discovery. More recently, Wendy delivered clinical and development phase consultancy for CB1 Bio Ltd, a company she founded.